/PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer,.
Sierra Oncology Reports First Quarter 2021 Results
News provided by
Share this article
– Topline Data Now Expected in Q1 2022 –
SAN MATEO, Calif., May 7, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2021. The first quarter of 2021 has been a hugely productive one for Sierra. We are excited to share that MOMENTUM enrollment has accelerated, and we now anticipate completing enrollment in June 2021. With this updated timing, we expect to report topline results in Q1 2022, said Stephen Dilly, MBBS, PhD, President and Chief Executive Officer of Sierra.
Sierra Oncology, Inc: Q1 Earnings Snapshot
May 7, 2021
FacebookTwitterEmail
VANCOUVER, British Columbia (AP) Sierra Oncology, Inc (SRRA) on Friday reported a loss of $19.9 million in its first quarter.
On a per-share basis, the Vancouver, British Columbia-based company said it had a loss of $1.71.
Sierra Oncology, Inc shares have risen 16% since the beginning of the year. The stock has climbed 48% in the last 12 months.
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on SRRA at https://www.zacks.com/ap/SRRA Top Picks In Shopping
Investegate |Sareum Holdings PLC Announcements | Sareum Holdings PLC: Half-year Report investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Sierra Oncology, Inc: Q4 Earnings Snapshot
March 11, 2021
FacebookTwitterEmail
VANCOUVER, British Columbia (AP) Sierra Oncology, Inc (SRRA) on Thursday reported a loss of $18 million in its fourth quarter.
The Vancouver, British Columbia-based company said it had a loss of $1.63 per share.
The results did not meet Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of $1.55 per share.
The oncology company posted revenue of $200,000 in the period.
For the year, the company reported that its loss narrowed to $80.9 million, or $7.70 per share. Revenue was reported as $300,000.
Sierra Oncology, Inc shares have fallen roughly 2% since the beginning of the year. The stock has increased 31% in the last 12 months.